TRIFLUSAL EUROPEAN PHARMACOPOEIA (EP) R

Not available outside of the UK & Ireland.

Biochem/physiol Actions

Triflusal is an anti-inflammatory antithrombotic platelet aggregation inhibitor with a 3-fold mechanism of action. It is an irreversible inhibitor of COX-1 inhibiting thromboxane A2, preventing aggregation; it preserves vascular prostacyclin, thus promoting anti-aggregant effect. Triflusal blocks phosphodiesterase leading to an increase in cAMP levels promoting anti-aggregant effect due to inhibition of calcium mobilization.

Caution

Please find SDS provided by EDQM here..

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

Unit quantity: 50 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.